Sims Andrew John Hugh MacIntyre

CFO Andrew MacIntyre buys 20,000 PSTV shares at $0.51; stock now -65.3% from 52-week high, but his 2 prior PSTV buys had 90d returns of +2459.1% and +2557.5%.

CFO Andrew MacIntyre purchased 20,000 shares of PLUS THERAPEUTICS at $0.51, increasing his holdings by 41.5% to 68.1K shares. The timing is notable: his prior two purchases at this ticker (2024-09-10 and 2024-05-08) both generated substantial 90-day returns (+2459.1% and +2557.5% respectively), and both were well-timed buys. His cross-ticker track record shows 2 prior buys with average 90d return of +2209.1% and a 100% win rate. However, the current context is concerning: PSTV stock has fallen -65.3% from its 52-week high of $39.25 and -38.8% in the past 30 days alone. The company reported quarterly revenue of $1.4M against a net loss of $4.4M, and while annual revenue grew 18.5%, the firm remains unprofitable. The purchase price of $0.51 represents a steep valuation compression from the prior highs, yet the execution against an already-weak price trajectory and unprofitable fundamentals differs materially from his prior two well-timed entries into this stock.

CFO Andrew MacIntyre buys 4,098 shares of PSTV at $1.27; stock down 54.6% from 52-week high; cluster pattern with 3 other insiders buying within 14 days.

Andrew MacIntyre, Chief Financial Officer, purchased 4,098 shares at $1.27, increasing his holdings from 5,717 to 9,815 shares (a 71.7% increase in his position). This purchase occurs while PSTV is trading 54.6% below its 52-week high of $74.25 and has declined 36.6% over the past 90 days. Notably, a cluster pattern shows 3 other insiders also bought within the past 14 days, suggesting broader internal conviction at current price levels. MacIntyre's prior PSTV purchase on 2024-05-08 was well-timed at the 90-day mark with a 1860.8% 90-day return, establishing a track record of favorable timing on this specific stock. Against this backdrop, the company remains unprofitable (net income of $-2.9M in the latest quarter, negative full-year net income) despite revenue growth of 36.5% year-over-year, creating a valuation context where insider accumulation may warrant investor scrutiny of underlying business momentum.